Drugs / Fluzopari
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05597527 | Nov 2022 → May 2025 | ovarian cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05392686 | Jun 2022 | lung cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzopari | “Fluzopari capsule” NCT05392686 ↗ |
| Action | Inhibit | “PARP inhibitor” NCT05392686 ↗ |
| Route | Oral | “maintenance oral PARP 100 mg twice daily” NCT05392686 ↗ |